Benefit of rebiopsy for deciding treatment strategy in rectal cancer

A case report

Kenta Kawasaki, Yasuo Hamamoto, Takeshi Suzuki, Kenro Hirata, Yasutaka Sukawa, Akiyoshi Kasuga, Yuichiro Hayashi, Hiromasa Takaishi, Kaori Kameyama, Takanori Kanai

Research output: Contribution to journalArticle

Abstract

Rebiopsy is considered an option for specific types of cancer, such as breast, non-small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a new treatment strategy based on the genetic profile of the cells, which may reflect the development of drug resistance or hormonal changes. For colorectal cancer, the presence of different genomic mutations between the primary tumor and its metastases is rare, and rebiopsy is therefore not generally performed. The present study reports the case of a 68-year-old man who was initially diagnosed with metastatic adenocarcinoma from a primary colorectal cancer, but was subsequently rediagnosed with metastatic neuroendocrine carcinoma based on the pathological rebiopsy results. The patient responded well to cisplatin and etoposide treatment, after not responding to initial FOLFOX treatment. In this case, rebiopsy resulted in a change in treatment regimen and improved the patient's quality of life and his long-term survival. This case indicates that, when a colorectal cancer patient is unresponsive to standard treatment, it may be beneficial for the clinician to suspect an atypical histological type, and to consider rebiopsy.

Original languageEnglish
Pages (from-to)3697-3700
Number of pages4
JournalOncology Letters
Volume14
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Rectal Neoplasms
Colorectal Neoplasms
Therapeutics
Neuroendocrine Carcinoma
Etoposide
Drug Resistance
Non-Small Cell Lung Carcinoma
Cisplatin
Neoplasms
Prostatic Neoplasms
Adenocarcinoma
Breast
Quality of Life
Clinical Trials
Neoplasm Metastasis
Mutation
Survival

Keywords

  • Biopsy
  • Colorectal cancer
  • Neuroendocrine cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Benefit of rebiopsy for deciding treatment strategy in rectal cancer : A case report. / Kawasaki, Kenta; Hamamoto, Yasuo; Suzuki, Takeshi; Hirata, Kenro; Sukawa, Yasutaka; Kasuga, Akiyoshi; Hayashi, Yuichiro; Takaishi, Hiromasa; Kameyama, Kaori; Kanai, Takanori.

In: Oncology Letters, Vol. 14, No. 3, 2017, p. 3697-3700.

Research output: Contribution to journalArticle

@article{b222196e51664027995ea9cb71563d32,
title = "Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report",
abstract = "Rebiopsy is considered an option for specific types of cancer, such as breast, non-small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a new treatment strategy based on the genetic profile of the cells, which may reflect the development of drug resistance or hormonal changes. For colorectal cancer, the presence of different genomic mutations between the primary tumor and its metastases is rare, and rebiopsy is therefore not generally performed. The present study reports the case of a 68-year-old man who was initially diagnosed with metastatic adenocarcinoma from a primary colorectal cancer, but was subsequently rediagnosed with metastatic neuroendocrine carcinoma based on the pathological rebiopsy results. The patient responded well to cisplatin and etoposide treatment, after not responding to initial FOLFOX treatment. In this case, rebiopsy resulted in a change in treatment regimen and improved the patient's quality of life and his long-term survival. This case indicates that, when a colorectal cancer patient is unresponsive to standard treatment, it may be beneficial for the clinician to suspect an atypical histological type, and to consider rebiopsy.",
keywords = "Biopsy, Colorectal cancer, Neuroendocrine cancer",
author = "Kenta Kawasaki and Yasuo Hamamoto and Takeshi Suzuki and Kenro Hirata and Yasutaka Sukawa and Akiyoshi Kasuga and Yuichiro Hayashi and Hiromasa Takaishi and Kaori Kameyama and Takanori Kanai",
year = "2017",
doi = "10.3892/ol.2017.6601",
language = "English",
volume = "14",
pages = "3697--3700",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Benefit of rebiopsy for deciding treatment strategy in rectal cancer

T2 - A case report

AU - Kawasaki, Kenta

AU - Hamamoto, Yasuo

AU - Suzuki, Takeshi

AU - Hirata, Kenro

AU - Sukawa, Yasutaka

AU - Kasuga, Akiyoshi

AU - Hayashi, Yuichiro

AU - Takaishi, Hiromasa

AU - Kameyama, Kaori

AU - Kanai, Takanori

PY - 2017

Y1 - 2017

N2 - Rebiopsy is considered an option for specific types of cancer, such as breast, non-small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a new treatment strategy based on the genetic profile of the cells, which may reflect the development of drug resistance or hormonal changes. For colorectal cancer, the presence of different genomic mutations between the primary tumor and its metastases is rare, and rebiopsy is therefore not generally performed. The present study reports the case of a 68-year-old man who was initially diagnosed with metastatic adenocarcinoma from a primary colorectal cancer, but was subsequently rediagnosed with metastatic neuroendocrine carcinoma based on the pathological rebiopsy results. The patient responded well to cisplatin and etoposide treatment, after not responding to initial FOLFOX treatment. In this case, rebiopsy resulted in a change in treatment regimen and improved the patient's quality of life and his long-term survival. This case indicates that, when a colorectal cancer patient is unresponsive to standard treatment, it may be beneficial for the clinician to suspect an atypical histological type, and to consider rebiopsy.

AB - Rebiopsy is considered an option for specific types of cancer, such as breast, non-small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a new treatment strategy based on the genetic profile of the cells, which may reflect the development of drug resistance or hormonal changes. For colorectal cancer, the presence of different genomic mutations between the primary tumor and its metastases is rare, and rebiopsy is therefore not generally performed. The present study reports the case of a 68-year-old man who was initially diagnosed with metastatic adenocarcinoma from a primary colorectal cancer, but was subsequently rediagnosed with metastatic neuroendocrine carcinoma based on the pathological rebiopsy results. The patient responded well to cisplatin and etoposide treatment, after not responding to initial FOLFOX treatment. In this case, rebiopsy resulted in a change in treatment regimen and improved the patient's quality of life and his long-term survival. This case indicates that, when a colorectal cancer patient is unresponsive to standard treatment, it may be beneficial for the clinician to suspect an atypical histological type, and to consider rebiopsy.

KW - Biopsy

KW - Colorectal cancer

KW - Neuroendocrine cancer

UR - http://www.scopus.com/inward/record.url?scp=85026325285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026325285&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.6601

DO - 10.3892/ol.2017.6601

M3 - Article

VL - 14

SP - 3697

EP - 3700

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -